Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study.

ABSTRACT:

Background and purpose

New prophylactics for migraine, targeting calcitonin gene-related peptide (CGRP), have recently emerged. Real-world data are important for a comprehensive understanding of treatment response. We assessed the consistency of response to erenumab, a monoclonal CGRP receptor antibody, in a real-world setting, in order to determine which patients may be considered responders in clinical practice.

Methods

All erenumab-treated patients (n = 100) completed a time-locked daily electronic diary, and an automated algorithm was used to monitor treatment response. Monthly migraine days (MMD), non-migrainous headache days, days of acute medication use (MAMD), well-being and coping with pain were assessed for a 6-month period. The primary outcome was reduction in MMD

SUBMITTER: de Vries Lentsch S 

PROVIDER: S-EPMC9291504 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature